MindImmune Therapeutics

Focus: MindImmune Therapeutics is a pre-revenue biotech focused on neuroinflammation therapies, targeting the intersection of immunology and neurology. Founded in 2015 and currently at Series A stage, the company operates from Kingston, RI with an early-stage pipeline in Alzheimer's disease and retinal degeneration.

Immunology Neurology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

SERIES A

Open Jobs

About MindImmune Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow MindImmune Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Study to Detect Dendritic Cell Recruitment in Human Retina

Dry Age Related Macular Degeneration

N/A

Clinical Trials (1)

NCT06872658Study to Detect Dendritic Cell Recruitment in Human Retina

N/A

Help build intelligence for MindImmune Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity in emerging neuroinflammation space with two active clinical programs in high-unmet-need indications (Alzheimer's, AMD)
Focused pipeline allows meaningful scientific contribution without corporate bureaucracy typical of larger organizations
Early-stage funding position suggests potential for significant equity upside if Series B and clinical programs advance

Watch Out For

Zero current job openings signal minimal near-term hiring and possible constrained headcount during Series A phase
No revenue generation, limited disclosed funding, and early-stage programs (exploratory phase only) create significant capital and timeline risk
Early-stage clinical data (dendritic cell detection studies, not traditional IND-stage programs) raises questions about technical feasibility and time to meaningful clinical readouts

Generated by Claude from MindImmune Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Exploratory Open Label Study for Development of a Method To Detect Dendritic Cells

Probable Alzheimer's Disease

N/A

Clinical Trials (1)

NCT05482867Exploratory Open Label Study for Development of a Method To Detect Dendritic Cells

N/A